Trial reportTheScientificWorldJournal2012
Population pharmacokinetics of vancomycin in Thai patients.
Trial report in TheScientificWorldJournal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 52 citations in OpenAlex.
- Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data.Journal of clinical pharmacy and therapeutics · 2021Trial
- Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens.European journal of clinical pharmacology · 2016Trial
- Exploring the effects of renal and cardiac functions on the pharmacokinetics of vancomycin in patients undergoing cardiac surgery: a population pharmacokinetic analysis.International journal of clinical pharmacy · 2026Article
- Generating and Modeling Virtual Patient Data from Published Population Pharmacokinetic Analyses: A Vancomycin Case Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Towards precision dosing of vancomycin in patients with allogeneic hematopoietic stem cell transplantation: a comparison of published population pharmacokinetic models.Antimicrobial agents and chemotherapy · 2025Article
- Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model Ensembling.Clinical pharmacokinetics · 2024Article
- Model-informed precision dosing of vancomycin for rapid achievement of target area under the concentration-time curve: A simulation study.Clinical and translational science · 2023Article
- Implementing Vancomycin Population Pharmacokinetic Models: An App for Individualized Antibiotic Therapy in Critically Ill Patients.Antibiotics (Basel, Switzerland) · 2023Article
- Model-informed precision dosing in vancomycin treatment.Frontiers in pharmacology · 2023Article
- Comparison of Race-Based and Non-Race-Based Equations for Kidney Function Estimation in Critically Ill Thai Patients for Vancomycin Dosing.Journal of clinical pharmacology · 2022Article
- Application of Machine Learning Classification to Improve the Performance of Vancomycin Therapeutic Drug Monitoring.Pharmaceutics · 2022Article
- Article
- Comparison of area under the curve for vancomycin from one- and two-compartment models using sparse data.European journal of hospital pharmacy : science and practice · 2022Article
- Vancomycin Population Pharmacokinetic Models in Non- Critically Ill Adults Patients: a scoping review.F1000Research · 2022Article
- Establishment of a population pharmacokinetics model of vancomycin in 94 infants with septicemia and its application in individualized therapy.BMC pharmacology & toxicology · 2021Article
- Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.Clinical pharmacokinetics · 2021Review
- Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan.Frontiers in pharmacology · 2021Article
- Population Pharmacokinetic Modeling of Vancomycin in Thai Patients With Heterogeneous and Unstable Renal Function.Therapeutic drug monitoring · 2020Article
- Vancomycin Area under the Curve and Pharmacokinetic Parameters during the First 24 Hours of Treatment in Critically Ill Patients using Bayesian Forecasting.Infection & chemotherapy · 2020Article
- An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults.Clinical pharmacokinetics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population pharmacokinetics of vancomycin in Thai adult patients was determined by non-linear mixed-effects approach using 319 vancomycin serum concentrations from 212 patients. The data were best fitted by a two-compartment model and it was used to examine the effect of patient characteristics on the vancomycin pharmacokinetics. In the final model, there was a linear relationship between vancomycin clearance, CL (L/h), and creatinine clearance calculated by Cockcroft-Gault equation, CL(Cr) (mL/min): CL = 0.044 × L(Cr). Meanwhile, volume of central compartment, V(1) (L), was linearly related with the age (years old): V(1) = 0.542 × Age. Intercompartment clearance (Q) and volume of peripheral compartment (V(2)) was 6.95 L/h and 44.2 L, respectively. The interindividual variability for CL, V(1), Q, and V(2) was 35.78, 20.93, 39.50, and 57.27%, respectively. Whereas, the intraindividual variability was 4.51 mg/L. Final model then was applied to predict serum vancomycin concentrations on validation group. Predictive performance revealed a bias of -1.43 mg/L (95% CI: -5.82-2.99) and a precision of 12.2 mg/L (95% CI: -1.60-26.16). In conclusion, population pharmacokinetic of vancomycin in Thai adult patients was developed. The model could be used to create vancomycin dosage regimen in the type of patient similar with the present study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.